Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
5.04
-0.17 (-3.26%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Neuphoria Therapeutics Revenue
Neuphoria Therapeutics had revenue of $662.72K in the quarter ending December 31, 2024. This brings the company's revenue in the last twelve months to $662.72K, down -832.17% year-over-year.
Revenue (ttm)
$662.72K
Revenue Growth
-832.17%
P/S Ratio
13.36
Revenue / Employee
$27,613
Employees
24
Market Cap
8.86M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
NEUP News
- 12 days ago - Neuphoria Provides a Review of 2024 and Highlights 2025 Plans - GlobeNewsWire
- 7 weeks ago - Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025 - GlobeNewsWire
- 2 months ago - Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - GlobeNewsWire
- 4 months ago - Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq - GlobeNewsWire